monosomy 1p Chromosome 1

Deletion of a portion of the p region of Crhomosome 1. Monosomy 1p36 (OMIM: 607872) is the most common terminal deltion syndrome in humans, occuring in 1 in 5000 births. It causes severe craniofacial abnormalities and developmental disabilities, including delayed growth, CRANIOSYNOSTOSES; MICROCEPHALY; CLEFT PALATE; eye and ear defects; congenital heart defects, seizures, and intellectual disability.

Also Known As:

Networked: 11 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Meningioma (Meningiomas)
2.	Tetraploidy
3.	Neoplasms (Cancer)
4.	Glioma (Gliomas)
5.	Sotos Syndrome

Experts

1.	Donato, Annalidia: 1 article (01/2019)
2.	Donato, Giuseppe: 1 article (01/2019)
3.	Malara, Natalia: 1 article (01/2019)
4.	Presta, Ivan: 1 article (01/2019)
5.	Vismara, Marco Flavio Michele: 1 article (01/2019)
6.	Hu, Huimin: 1 article (02/2016)
7.	Jiang, Tao: 1 article (02/2016)
8.	Li, Mingyang: 1 article (02/2016)
9.	Liu, Yanwei: 1 article (02/2016)
10.	Wang, Zheng: 1 article (02/2016)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to monosomy 1p Chromosome 1:

1.	Proteins (Proteins, Gene)FDA Link 02/01/2016 - "In the present study, we determined that co-deletion 1p/19q was associated with reduced Ki-67 protein level based on analysis of 354 ODs. " 11/01/1999 - "The complete activity loss of ALPL and the immunologically detected loss of ALPL protein in areas of meningiomas with monosomy 1p indicate a cytogenetically undetectable inactivation of the homologous Alpl allele. "
2.	Alkaline PhosphataseIBA 05/11/2002 - "[Monosomy 1p and alkaline phosphatase in meningiomas. " 11/01/1999 - "The aim of this study was to evaluate the significance of monosomy 1p and enzyme activity loss of tissue nonspecific alkaline phosphatase (ALPL), whose gene maps to chromosome 1p36.1-p34, as parameters for the diagnosis of progression-prone meningiomas. "
3.	Ferritins (Ferritin)IBA 07/01/1996 - "Furthermore a significant correlation of the serological (NSE, ferritin, LDH) and biological factors (N-myc, deletion 1p, di/tetraploidy) was detected in this study. "
4.	EnzymesIBA 11/01/1999 - "The aim of this study was to evaluate the significance of monosomy 1p and enzyme activity loss of tissue nonspecific alkaline phosphatase (ALPL), whose gene maps to chromosome 1p36.1-p34, as parameters for the diagnosis of progression-prone meningiomas. "
5.	Biological FactorsIBA 07/01/1996 - "Furthermore a significant correlation of the serological (NSE, ferritin, LDH) and biological factors (N-myc, deletion 1p, di/tetraploidy) was detected in this study. "
6.	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/01/2023 - "Currently, classification of neoplasms, especially regarding gliomas, is established on molecular mutations in isocitrate dehydrogenase (IDH) genes and the presence of co-deletion 1p/19q. " 01/01/2019 - "Nowadays, tumors classification, especially that regarding gliomas, is based on molecular features such as mutations in isocitrate dehydrogenase (IDH) genes and the presence of co-deletion 1p/19q. "
7.	Glucose (Dextrose)FDA LinkGeneric 02/01/1995 - "Monosomy 1p is correlated with enhanced in vivo glucose metabolism in meningiomas."

Therapies and Procedures

1.	Therapeutics 09/01/2007 - "Deletion 1p is associated with a significantly shorter remission and survival in patients undergoing high-dose therapy and a single autologous transplant for myeloma." 09/01/2005 - "Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q."
2.	Ligation 01/01/2008 - "Multiplex Ligation-dependent Probe Amplification was applied to screen for nine microdeletions/duplications related to ID syndromes (Williams 22q11-deletion, 1p-deletion, Miller-Dieker, Smith-Magenis, Prader-Willi, Alagille, Saethre-Chotzen and Sotos syndrome). "
3.	Drug Therapy (Chemotherapy) 02/16/2007 - "For treatment purposes, the combined deletion 1p/19q identifies the anaplastic type of oligodendrogliomas that are more responsive to chemotherapy. "